Immunotherapy as cancer treatment and the role of nursing
DOI:
https://doi.org/10.33448/rsd-v10i6.15902Keywords:
Immunotherapy; Cancer; Neoplasms; Nursing.Abstract
Objective: The objective of this work was to describe the techniques and applications of immunotherapy, how they interact with tumors and the perspectives and benefits of these new therapies for patients, presenting the different forms of treatment against cancer, identifying the consequences, verifying the production scientific about immunotherapy with the purpose of demonstrating the efficacy for the treatment of cancer, presenting the advantages of the therapies used and the advances in the discoveries of new therapeutic methods, and pointing out the role of nursing in immunotherapy. Methodology: This is an integrative review with descriptive analysis, which has been considered, nowadays, a very important tool in the elaboration of studies in the health field. Results: General information on the 11 articles included in this integrative review is described. All results were interpreted and synthesized, by comparing the data shown in the analysis of the articles to the theoretical framework. Conclusion: Immunotherapy is a treatment for cancer in development. There are some important points to be reviewed about the role of nursing in the treatment of different types of tumors. Because of their combination or the order of treatment involved, they are very broad and must have more than one protection route different from existing treatments and determine an ideal schedule.
References
Amador, D. D., Gomes, I. P., Coutinho, S. E. D., Costa, T. N. A. & Collet, N. (2010). A vivência do cuidado em oncologia pediátrica e a busca pela produção do conhecimento. Rev enferm. UFPE on line; 4 (2): 666-72. http://www.revista.ufpe.br/revistaenfermagem/index.php/revista/article/view/851.
Antonia, S., James. J. L. & Ascierto, P. A. (2014). Immunooncology combinations: a review of clinical experience and future prospects. Clinical Cancer Research. 20 (24), 6258-6268.
Backes, V. M. S., Lino, M. M., Prado, M. L. do., Reibnitz, K. S. & Canaver, B. P. (2008). Competência dos enfermeiros na atuação como educador em saúde. Rev Bras Enferm. 61(6), 858-65. http://www.scielo.br/pdf/reben/v61n6/a11v61n6.pdf.
Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsh, L. & McCoy, A. S. (2016). Cancer Immunotherapy: An evidencebased overview and implications for practice. Clinical journal of oncology nursing. 2, 21.
Borghaei, H., Smith, M. R. & Campbell, K. S. (2009). Immunotherapy of cancer. European Journal of Pharmacology. 625, 41-54.
Bray, F. et al. (2018). Global cancer statistics estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, Hoboken; 68 (6) 394-424.
Coates, A. S. (1999). Breast cancer: delays, dilemmas, and delusions. Lancet, 353(9158), 1112-3.
Collins, L. K., Chapman, M. S., Carter, J. B. & Samie, F. H. (2017). Cutaneous adverse effects of the immune checkpoint inhibitors. Current Problems in Cancer. 41(2), 125-28.
Couzin-Frankel, J. (2013). Cancer immunotherapy. Science, vol. 342, Issue 6165, p. 1417.
Curry, J. L, Tetzlaff, M. T., Nagarajan, P., Drucker. C., Diab, A. & Hymes, S. R. (2017). Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 44, 158-76.
Durkee, B. Y., Qian, Y., Pollom, E. L., King, M. T., Dudley, A. S. & Shaffer, J. L, et al. (2016). Cost Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 34(9), 902-9.
Ferreira, J. C. O. A. & Kurcgant, P. (2009). Capacitação profissional do enfermeiro de um complexo hospitalar de ensino na visão de seus gestores. Acta Paul Enferm. 22(1),31-6. http://www.scielo.br/pdf/ape/v22n1/a05v22n1.pdf 7.
Freire, D. (2019). Imunoterapia: a virada do sistema imunológico contra o câncer. Cienc. Cult. vol.71 no.4 São Paulo. /10.21800/2317-66602019000400006.
Hanahan, D. & Weinberg, R.A. (2000). The hallmarks of cancer. Cell. 100 (1), 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9.
Immunotherapy for Melanoma Skin Cancer. (2018). American Cancer Society. https://www.cancer.org/cancer/melanoma-skincancer/treating/immunotherapy.html.
Institute, N. C. (2010). Common Terminology Criteria for Adverse Events (CTCAE): Version 4.032010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06 14_QuickReference_8.5x11. pdf.
Instituto Nacional de Câncer (2015). Coordenação de Prevenção e Vigilância: Estimativa 2016: Incidência de câncer no Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva – Rio de Janeiro: INCA.
Keefe, D. M. . & Gibson, R. J. (2007). Mucosal injury from targeted anti-cancer therapy. Supportive Care Cancer. 15, 483-90.
Knechtel, Maria do Rosário. Metodologia da pesquisa em educação: uma abordagem teórico-prática dialogada. Curitiba: Intersaberes, 2014.
Kronbichler, A. et al. (2015). Frequency, risk factors and prophylaxis of infection in ANCA – associated vasculitis. Euro Journal Clinical Invest. 346 – 368.
Mathers, et al. (2013). Anticancer Therapy. J Pharmacovigilance. 1 (4), 1-4.
McNutt, M. (2013). Cancer immunotherapy. Science. 342, (6165), 1417.
Mellman, I., Coukos, G. & Dranoff, G. (2011). Cancer immunotherapy comes on age. Nature. 480, 480-9.
Mendes, K. D. S., Silveira, R. C. C. P. & Galvão, C. M. (2008). Revisão integrativa: Método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm, Florianópolis. 17(4), 758-64.
Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. (2014). New insights into câncer immunoediting and its three componente phase – elimination, equilibrium and escape. Current opinion in immunology. 27, 16-25.
Mittal, D., Gubin, M. M., Schreiber, R. D., Smyth, M. J. (2014). New insights into cancer immunoediting and its three componente phase – elimination, equilibrium and escape. Current opinion in immunology. 27,16-25.
Naidoo, J. et al. (2015). Toxicities of the anti-PD-1and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375 – 2391.
Oliveira, J. L. C. de. Et al. (2009). Interface entre acreditação e segurança do paciente: perspectivas da equipe de enfermagem. Ver.Esc. Enferm. USP, 54:e 03604. /10.1590/S1980-220X2018053703604.
Oncologia. (2021). O que é imunoterapia? http://www.oncoguia.org.br/conteudo/o-que-e-imunoterapia/7957/922/.
Parker, C., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. ALSYMPCA Investigators. N Engl J Med. 369 (3), 213-23.
Parkhill, A. L. (2013). Oral Mucositis and Stomatitis Associated with Conventional and Targeted Anticancer Therapy. J Pharmacovigilance. 1,4,1-4.
Parkin, D. M., Boyd, L., & Walker, L. C. (2010). The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 105 (2), 77-81.
Peterson, D. E., O’Shaughnessy, J. A., Rugo, H. S, Elad S, Schubert, M. M., & Viet, C. T et al. (2016). Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Medicine. 5 (8), 1897-1907.
Postow, M. (2015). Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology education book/ ASCO American Society of Clinical Oncology Meeting, pg. 76 – 83.
Rosenberg, S. A. & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348(6230), 62-8.
Sainsbury, r., Johnston, c. & Haward, B. (1999). Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet., London, 353, 1132-1135.
Secoli, S. R., Padilha, K. G. & Leite, R. C. B. O. (2005). Avanços tecnológicos em oncologia: reflexões para a prática de enfermagem. Revista Brasileira de Cancerologia Enfermería Global Nº 37 Abril 2015 Página 322;51(4), 331-337. http://www.inca.gov.br/rbc/n_51/v04/pdf/revisao4. pdf.
Sibaud, V. (2018). Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. American of Journal Clinical Dermatology. 19(3), 345-361.
Silva, W. D. & Mota, I. B. (2003). Imunologia básica e aplicada. (5a ed.), Guanabara Koogan, 2003.
Souza, M. T., Silva, M. D. & Carvalho, R. (2010). Revisão integrativa: O que é e como fazer. Einstein. 8 (1), 102-6.
Squibb, B. (2016). Opdivo (nivolumab): Immune-Mediated Adverse Reactions Management Guide. http://www.opdivohcp.bmscustomerconnect.com/servelet/servelet.FileDownload?file=00Pi00000Hj19REAR.
Stiefel, F. (2006). Understanding why women delay in seeking help for breast cancer symptoms. Letter to the Editor. Journal of Psychosomatic Research. Oxford, 60, 309- 310.
Stumm, E. M. F., Leite, M. T. & Maschio, G. (2008). Vivências de uma equipe de enfermagem no cuidado a pacientes com câncer. Cogitare Enferm. 13 (1), 75-82. /10.5380/ce.v13i1.11955.
Voena, C. & Chiarle, R. (2016). Advances in cancer immunology and cancer immunotherapy. Discovery medicine. 21, 125-33.
Yaddanapudi, K., Mitchell, R. A. & Eaton, J. W. (2013). Cancer vaccines: Looking to the future. Oncoimmunology. 2 (3), 23403.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Beatriz Alves Fontoura; Eliane de Sousa Caixeta; Lindalva de Souza Silva; Renata Gabrielle Campos da Silva; Vanessa Caroline Batista Pereira; Marco Aurélio Ninomia Passos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
